Now Playing
Opinion|Videos|November 30, 2023
Radiation Safety Considerations for Patients With Prostate Cancer
Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Advertisement
Advertisement
Trending on Urology Times
1
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
ESMO 2026: Key presentations across genitourinary oncology
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5